Montag A & Associates Inc. reduced its position in Cencora, Inc. (NYSE:COR - Free Report) by 11.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 13,752 shares of the company's stock after selling 1,864 shares during the period. Montag A & Associates Inc.'s holdings in Cencora were worth $3,090,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Lake Street Advisors Group LLC raised its stake in Cencora by 1.3% during the 3rd quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock valued at $769,000 after acquiring an additional 43 shares during the last quarter. Venturi Wealth Management LLC raised its stake in Cencora by 1.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company's stock valued at $1,001,000 after acquiring an additional 46 shares during the last quarter. Prime Capital Investment Advisors LLC raised its stake in Cencora by 1.2% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock valued at $848,000 after acquiring an additional 46 shares during the last quarter. Shepherd Financial Partners LLC raised its stake in Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after acquiring an additional 46 shares during the last quarter. Finally, WASHINGTON TRUST Co raised its stake in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.
Cencora Trading Up 1.6 %
Shares of Cencora stock traded up $3.93 during trading hours on Wednesday, reaching $245.37. 1,558,569 shares of the company's stock were exchanged, compared to its average volume of 1,511,237. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $262.26. The firm has a market capitalization of $47.58 billion, a price-to-earnings ratio of 34.90, a price-to-earnings-growth ratio of 1.30 and a beta of 0.49. The company has a fifty day moving average of $239.11 and a 200-day moving average of $237.42. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.
Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.
Wall Street Analysts Forecast Growth
Several research firms have commented on COR. Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. UBS Group increased their target price on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Robert W. Baird increased their target price on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Finally, Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $277.90.
Get Our Latest Analysis on COR
Insider Buying and Selling
In related news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company's stock.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
